Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
Completed
Genaissance Pharmaceuticals
Phase 3
2006-02-01
This study is designed to determine the safety and effectiveness of vilazodone for major
depressive disorder and to discover genetic markers associated with response. This study will
enroll approximately 400 patients.
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
Completed
Forest Laboratories
Phase 3
2007-12-31
This open label 52-week clinical trial is designed to assess the safety and tolerability of
vilazodone and to analyze genetic markers of response to vilazodone in adult patients
diagnosed with MDD. This study will enroll approximately 600 patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
